# Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

> **NCT01097057** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Ifosfamide
- **PROCEDURE:** Leukapheresis
- **DRUG:** Plerixafor
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01097057
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-09
- **Primary completion:** 2013-09
- **Final completion:** 2017-12-26
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01097057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01097057, "Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01097057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*